News Hub

Real-time financial, economic, and global news with market-focused context and analysis.

Coverage spans equities, macroeconomic data, commodities, currencies, technology, politics, and global events—paired with analysis that highlights why each development matters for traders and investors. From breaking headlines to hourly market snapshots and in-depth articles, the News Hub is designed to help you stay informed, oriented, and ahead of market-moving events.

  • German 10-year Bund yield rose to 2.95% as eurozone government yields ticked up and crude oil gained nearly 1% after U.S.-Iran talks volatility.
  • Spanish bankers say EU regulatory simplification could unlock over €2 trillion in additional bank lending capacity across the bloc.
  • Semiconductor rally extended with Allegro leading double-digit gains, reinforcing investor appetite for chip names.
  • J.P. Morgan put Vestas on positive Catalyst Watch, citing strong onshore demand and potential H1 guidance upgrade.
  • Avio shares rose after a €35m MBDA production order and Ariane 6 support boosted revenue visibility.
  • Australia reported a suspected mainland H5N1 case in Western Australia, with confirmatory testing and national response plans underway.
  • Andy Burnham won the Makerfield by-election with 54.8%, intensifying talk of a leadership challenge to Keir Starmer.

Latest Articles

Jefferies Flags European Capital-Goods Names Set to Benefit from Data Centers, Power and Automation Trends

Jefferies Flags European Capital-Goods Names Set to Benefit from Data Centers, Power and Automation Trends

Jefferies has identified a group of European capital-goods companies that it believes are well positioned to capture growth from data center expansion, power-infrastructure investment and industrial automation. The broker highlights expected revenue drivers, margin improvements and capital allocation dynamics across Legrand, Siemens, Siemens Energy…

AMD shares slide after Q4 2025 results despite modest beat; investors flag OpenAI dependency and China sales

AMD shares slide after Q4 2025 results despite modest beat; investors flag OpenAI dependency and China sales

Advanced Micro Devices reported a modest beat and raised guidance for the quarter, but its stock fell about 8% in after-hours trading. Investors and analysts highlighted concerns over the company’s exposure to the OpenAI project, the quality of a China-driven portion of the revenue beat, and potential bottlenecks in the MI450 ramp. Management reite…

Russia Faces Sharper-Than-Expected Budget Gap as Oil Revenue Slips

Russia Faces Sharper-Than-Expected Budget Gap as Oil Revenue Slips

Confidential calculations by economists tied to a government think tank indicate Russia's budget shortfall could widen to 3.5-4.4% of GDP in 2026, far above the government's 1.6% target. The projected deterioration reflects an assumed 18% fall in energy revenues, lower total budget receipts and a potential rise in spending, while fiscal reserves ma…

Mizuho trims AMD price target to $275, cites higher AI-related spending

Mizuho trims AMD price target to $275, cites higher AI-related spending

Mizuho reduced its 12-month price target for Advanced Micro Devices to $275 from $285 while retaining an Outperform rating, pointing to rising operating expenses tied to AI hardware and software investment. AMD reported quarterly results roughly in line with expectations, raised March-quarter revenue guidance above consensus, and highlighted a robu…

CRWE: Deep Price Discount and Heavy Shorting — A Tactical Core Long

CRWE: Deep Price Discount and Heavy Shorting — A Tactical Core Long

CRWE is trading near its shorter-term moving averages while showing elevated episodic short volume and an insider buy on 07/23/2024. Liquidity is low and the listing is on OTC, but the technicals and short activity create an asymmetric risk/reward for a disciplined core long. This trade is intended as a position-sized idea for a 180-trading-day hor…

B.Riley Sticks With Buy on Nuvation Bio as Ibtrozi Sales Accelerate

B.Riley Sticks With Buy on Nuvation Bio as Ibtrozi Sales Accelerate

B.Riley has reiterated a Buy rating and set a $12.00 price target on Nuvation Bio Inc (NYSE:NUVB), pointing to accelerating commercial traction for the company’s ROS1-positive lung cancer therapy Ibtrozi. Recent IQVIA WSP weekly figures show the drug reaching a new weekly sales peak through the week ending January 23, 2026, while quarter-to-quarter…